HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Metastatic Insulinoma Pancreatic Neuroendocrine Tumor Treated With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy: A Suggested Protocol.

Abstract
A 70-year-old woman presented with frequent episodes of hypoglycemia. Imaging revealed a 6-cm pancreatic mass with several liver lesions. The pancreatic mass was resected and confirmed to be a well-differentiated insulinoma. Surgery improved but did not resolve her hypoglycemic episodes, and she was referred for peptide receptor radionuclide therapy with 177Lu-DOTATATE to treat her residual disease. A modified protocol with a continuous IV dextrose infusion was used, and the treatments were well tolerated. After 4 induction and 2 maintenance treatments, her hypoglycemic symptoms resolved completely and her disease stabilized. She has been progression free for 24 months.
AuthorsWilliam Makis, Karey McCann, Alexander J B McEwan
JournalClinical nuclear medicine (Clin Nucl Med) Vol. 41 Issue 1 Pg. 53-4 (Jan 2016) ISSN: 1536-0229 [Electronic] United States
PMID26562579 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Organometallic Compounds
  • Receptors, Peptide
  • lutetium Lu 177 dotatate
  • Octreotide
Topics
  • Aged
  • Female
  • Humans
  • Insulinoma (pathology, radiotherapy)
  • Neoplasm Metastasis
  • Neuroendocrine Tumors (pathology, radiotherapy)
  • Octreotide (analogs & derivatives, therapeutic use)
  • Organometallic Compounds (therapeutic use)
  • Pancreatic Neoplasms (pathology, radiotherapy)
  • Receptors, Peptide (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: